Concourse Financial Group Securities, Inc. T Scan Therapeutics, Inc. Transaction History
Concourse Financial Group Securities, Inc.
- $0
- Q2 2025
Number of Shares
0
Previous 0
NaN%
Holding current value
$0
Previous $0
NaN%
% of portfolio
100.0%
Previous 100.0%
Shares
17 transactions
Others Institutions Holding TCRX
# of Institutions
78Shares Held
38.2MCall Options Held
0Put Options Held
0-
Lynx1 Capital Management LP San Juan, PR7.86MShares$9.74 Million3.37% of portfolio
-
Bvf Inc San Francisco, CA5.23MShares$6.48 Million0.3% of portfolio
-
Black Rock Inc. New York, NY4.46MShares$5.53 Million0.0% of portfolio
-
Baker Bros. Advisors LP New York, NY2.78MShares$3.45 Million0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.32MShares$2.87 Million0.0% of portfolio
About TScan Therapeutics, Inc.
- Ticker TCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 18,929,800
- Market Cap $23.5M
- Description
- TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell ...